Galmed Pharmaceuticals Ltd

Market cap: $1,897,546

Exchange: NAS

Sector: Health Technology

Share
Tweet

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Key Statistics

Company Name

Galmed Pharmaceuticals Ltd

Average Volume (10 days)

486,339

Average Volume (30 days)

289,432

Moving Average (50 days)

$0.3584

Moving Average (200 days)

$0.3854

Ex-Divided Date

n/a

Dividend Yield

0

P/E Ratio

0

Market Cap

1,897,546

Shares Outstanding

5,045,324

52-Week High Split Adjust Only

117

52-Week Low Split Adjust Only

0.26

Employee Count

23

Beta

0

Next Earnings Date

TTM Dividend Rate Per Share

0

Price Changes

Past 5 days

-0.05%

Past 30 days

0.23%

Past 3 months

-0.17%

Past 6 months

-0.08%

Past year

-0.99%

Past 2 years

-1%

Past 5 years

-1%

Max % Change

-1%

PEER GROUP COMPARATIVE PERFORMANCE

NameTickerPrice/Sales (ttm)Price/Book (ttm)Forward P/EPEG RatioEV/Revenue
Galmed Pharmaceuticals LtdGLMDn/an/a-1.8n/an/a
Peer AvgN/A1.701.633.21.702.03
Catalent Inc.CTLT4.754.39n/a4.755.33
ANI Pharmaceuticals IncANIP2.052.15n/a2.052.79
Eagle Pharmaceuticals IncEGRXn/an/a12.8n/an/a
Evoke Pharma IncEVOKn/an/an/an/an/a